|[March 17, 2014]
OncoSec Medical to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
SAN DIEGO --(Business Wire)--
OncoSec Medical Inc. (OTCQB: ONCS),
a company developing its advanced-stage ImmunoPulse DNA-based
immunotherapy to treat solid tumors, today announced that Punit Dhillon,
President and CEO, will present a corporate overview of the company at
the 2nd Annual Sachs Cancer Bio Partnering & Investment Forum
at the New York Academy of Sciences on Wednesday, March 19th
at 3:00 p.m. (EST).
A webcast will be available one week after the presentation on OncoSec's
web page at http://www.oncosec.com.
About the Sachs Cancer Bio Partnering & Investment Forum
2nd Annual Sachs Cancer Bio Partnering & Investment Forum aims to bring
together thought leaders from cancer research institutes, patient
advocacy groups, pharma, and biotech to facilitate partnering and
investments. Over 200 delegates are expected to attend, with meeting
facilities and an online meeting system to make the event transactional.
The Sachs Cancer Bio Partnering & Investment Forum will take place March
19th 2014, at the New York Academy of Sciences, at 250
Greenwich Street, New York, NY.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a
biopharmaceutical company developing its advanced-stage ImmunoPulse
immunotherapy to treat solid tumors. OncoSec Medical's core technology
leverages a proprietary electroporation platform to enhance the local
delivery and uptake of IL-12 and other DNA-based immune-modulating
agents. Clinical studies of ImmunoPulse have demonstrated positive
safety and preliminary efficacy in the treatment of various skin
cancers, as well as the potential to initiate a systemic immune response
without the toxicities associated with other systemic treatments.
OncoSec's clinical programs currently include three Phase 2 trials
targeting metastatic melanoma, Merkel cell carcinoma and cutaneous
T-cell lymphoma (http://clinicaltrials.gov/ct2/results?term=oncosec&Search=Search).
As the company continues to evaluate ImmunoPulse in these indications,
it is also investigating additional indications and efficacious
combination approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward-looking statements." Forward-looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical's filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
[ Back To TMCnet.com's Homepage ]